Breast Cancer Clinical Trial
Official title:
Diet Composition, Weight Control, and Breast Carcinogenesis
In the United States, overweight (BMI > 25 but < 30 Kg/m2) and obesity (BMI > 30Kg/m2) are
increasing at epidemic rates. A significant association exists between being overweight or
obese and breast cancer recurrence and survival. However, evidence continues to accumulate
indicating that achieving or maintaining a healthy weight for height (Body Mass Index, BMI,
18.5-25Kg/m2) is associated with a reduced risk for breast cancer and with a decrease in
breast cancer associated mortality. Despite this, there is a lack of randomized controlled
trials exploring this association and how the process of fat loss or being successful in
actually reaching a healthy weight for height differentially affects biomarkers for cancer
recurrence.
Many dietary approaches for weight loss are currently available to the public, and each
purports to offer advantages. However, there is little scientific evidence to indicate how
these dietary approaches, some of which vary markedly in the foods that they limit or
exclude, affect biomarkers for breast cancer risk. In particular, it is not know whether the
critical factor in relation to weight and breast cancer is simply weight loss (negative
energy balance), irrespective of the manner in which it is achieved, or if certain dietary
approaches affect breast cancer risk biomarkers more favorably than others. Published data
from our laboratory suggest that dietary pattern does matter, and therefore the goal of this
study is to investigate the effects of two popular weight loss dietary approaches that
differ in the extent to which they limit carbohydrate or fat consumption (with effects on
dietary glycemic load) compared to a usual care group on prognostic markers for cancer
recurrence in postmenopausal breast cancer survivors. The investigators hypothesize that in
addition to the anticipated effects of fat loss on circulating levels of bioavailable sex
steroid hormones, that the effects of excess fat on breast cancer prognosis can be
attributed to three interrelated metabolic processes that affect cancer progression: altered
glucose metabolism, chronic inflammation and excessive cellular oxidation.
This study is designed to answer questions about how a dietary pattern either high or low in
dietary carbohydrate and fat availability and fat loss influence metabolic and hormonal
processes that may affect breast cancer recurrence. The investigators hypothesize that in
addition to the anticipated effects of fat loss on circulating levels of bioavailable sex
steroids, that the effects of excess fat on breast cancer prognosis can be attributed to
three interrelated metabolic processes: altered glucose metabolism (IGF-1, IGFBP-3, glycated
proteins), chronic inflammation (C-reactive protein, IL-6, TNF-alpha) and excessive cellular
oxidation (8-hydroxy-2-deoxyguanosine and 8-isoprostane F-2 alpha).
A 6 month intervention study involving 370 post menopausal women who have been treated for
breast cancer is proposed. Randomized women, stratified by resected stage, systemic adjuvant
therapy and body mass index (> 25 and < 35 Kg/m2), will serve as either a non-intervention
control group or will follow a tailored diet-physical activity program designed to create a
weekly negative energy balance equivalent to 3500 kcal. The intervention groups will receive
the same physical activity protocol, but one of two diets that differ in dietary pattern.
The specific aims are: Aim 1. Does a dietary pattern either high or low in available
carbohydrate and fat alter the pattern of change observed in circulating factors involved in
glucose homeostasis, chronic inflammation, cellular oxidation, and steroid hormone
metabolism during progressive loss of body fat? The investigators will also examine how
observed changes in these circulating factors related to changes indicators of breast cancer
recurrence. Aim 2. Do circulating factors associated with glucose homeostasis, chronic
inflammation, and cellular oxidation display the same pattern of change in response to
progressive fat loss as circulating analytes associated with sex steroid metabolism?
Analytes of interest will be measured monthly throughout the study. Aim 3. Does dietary
glycemic load affect the magnitude or rate of fat loss? Plasma adipokines such as leptin and
adiponectin and plasma ghrelin will be measured to provide biological determinants that may
help explain differences in response.
The work proposed in this application should provide quantitative data about the importance
of the magnitude of fat loss on metabolic and hormonal processes involved in cancer
recurrence and provide guidance about effective dietary approaches that maximize weight loss
benefits on breast cancer prognosis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |